Risk analysis for products in development
RAPID studies the health effects of exposure to hazardous substances in the workplace, in the environment, and after intake. It develops innovative approaches for early prediction of health effects resulting from such exposure, as well as measuring, modelling, and managing exposure. We do this research within national and international legal frameworks, and we focus on earlier process phases, such as the development of new ingredients, materials, and products by means of Safe and Sustainable by Design concepts.
Health risks of hazardous substances
On the basis of RAPID, we’re increasingly modelling health risks of hazardous substances for humans in order to reduce costs and increase speed. In doing so, we combine in-depth knowledge of risk analysis and statistics with practical experience in the field of innovative experimental research. This includes research into toxicology, immune health, epidemiology, chemistry, human exposure, statistics, and modelling. For example, we’re developing integrated strategies that predict human health risks with high precision and make minimal use of animal studies.
We use the Diamonds data platform to integrate data for Life Sciences in various domains, such as risk assessments of substances, safety assessments of drug targets, and decision support systems for personalised advice.
The focus of RAPID is to demonstrate whether innovations work to a sufficient degree (proof of principle), and to deliver a first application, in which the working principle is used (proof of market). With external partners, we shape the further upscaling of a significant part of these innovations in the private market.
We’re strongly internationally oriented and focus on industrial challenges within three business sectors:
We also support governments with their research issues.
Applications and impact
Some examples of our applications with their impact on society:
- Based on research among a large number of industry organisations, we conclude that many Dutch citizens may be exposed to nanoparticles in the workplace. These results serve as a basis for new large-scale research into nanoparticle exposure among Dutch workers.
- We’ve shown that the concentration of allergens in foodstuffs can cause public health risks through cross-contamination. A model we developed calculates the number of consumers who have an allergic reaction to a certain concentration of an allergen in food. Our research and the international database managed by TNO, with more than 3500 sensitivity thresholds in individual patients with food allergies, form the basis for WHO/FAO advice on safe limits for allergens in food.
- RAPID plays a leading role in developing the multidisciplinary exposome paradigm. The exposome identifies multifactorial health stressors, resulting from multiple and lifelong exposure, in relation to health effects. The exposome is taking on an increasingly significant role in determining/measuring health and developing strategies for health interventions.
- RAPID has developed a digital text-mining application called Target Tri to help pharmaceutical companies with the early selection of new drug targets. Target Tri can quickly establish the safety and effectiveness of targets.
Connecting the dots for effective disease prevention
Read our white paper on how environmental exposures are a major risk factor for disease.
Carina de Jong-RubinghFunctie:Research Manager
Looking for an expert?View all experts
TNO publishes fully integrated Annual Report 2022
TNO's Annual Report 2022 is published. For the first time, it concerns a fully integrated annual report, in which sustainability is fully incorporated into the general annual report.
Ex vivo organ perfusion provides accurate drug development data
TNO uses ex vivo normothermic organ perfusion to more accurately determine ADME processes for specific compounds and accelerate drug development.
International Women's Day
Celebrating International Women's Day. Diversity is essential to innovate in today’s world. Different perspectives are needed to enrich our work, to make it stand out and to address the challenges we face in our time.
Public Private Partnership supports intestinal health in early life
Public Private Partnership Fontanelle works on the solutions that contribute to long-term effects on (gut) health through the development of an integrated approach of in vitro, ex vivo and AI models to test the potential health benefits of specialised nutrition for infants and young piglets.
WHO launches new package to measure early development of children up to 36 months
Today the World Health Organization (WHO) launched the Global Scales for Early Development (GSED). TNO was part of the team that developed the GSED package. With the Developmental score (D-score), TNO provided the backbone for the GSED.